{
  "documents": [
    "Kimberley Clinical Protocols Chronic Kidney Disease (chronic kidney disease) Screen annually for patients with any of the following Case Definitions risk factors: Aboriginal or Torres Strait Islander person aged ≥ 15 Chronic Kidney Disease (chronic kidney disease) is either of the years; Non-Aboriginal people aged ≥ 60 years; following, persisting for at least three months, Smoking; repeated on at least two occasions: Obesity (body mass index 30kg/m2); 1. Markers of kidney damage (eg. proteinuria, Family history of chronic kidney disease; haematuria or structural abnormalities on History of cardiovascular disease (eg. stroke/CVA, renal imaging) and / or: heart attack/myocardial infarction, peripheral vascular disease/peripheral vascular disease); 2. glomerular filtration rate 60 milliliters per minute/1. 73m2. Hypertension (hypertension); Diabetes; Both estimated glomerular filtration rate and albumin-creatinine ratio are required to determine Previous acute kidney injury (acute kidney injury); the stage and risk category of chronic kidney disease, as Use of nephrotoxic drugs (eg. NSAIDS). albuminuria is one of the biggest known risk factors for progression to End Stage Kidney Patients assessed as not having risk factors should be Disease (end-stage kidney disease). regularly screened for the development of risk factors over time. TABLE 1: Kidney Disease: Improving Global Outcomes STAGING OF chronic kidney disease albumin-creatinine ratio (magnesium/mmol) Screening for chronic kidney disease requires: estimated glomerular filtration rate Normal MicroMacro- Blood pressure (blood pressure) measurement; and 3. 0 albuminuria albuminuria Blood test for urea, electrolytes, creatinine (UEC); 3. 0-30 30 and Stage 1 Not chronic kidney disease MODERATE HIGH RISK unless RISK chronic kidney disease chronic kidney disease Urine test for albumin: creatinine ratio (albumin-creatinine ratio): estimated glomerular filtration rate ≥90 haematuria, o Dipstick prior to sending and document result; Stage 2 structural or If leucocytes, blood and/or nitrates consider estimated glomerular filtration rate 60pathological o abnormalities possible UTI / STI (see Table 2). 89 present Stage 3 MODERATE HIGH RISK VERY HIGH Considerations in interpreting screening results: RISK chronic kidney disease chronic kidney disease RISK chronic kidney disease estimated glomerular filtration rate 45- Creatinine levels vary with muscle mass; estimated glomerular filtration rate on 59 laboratory reports may under or overestimate renal Stage 3b HIGH RISK VERY HIGH estimated glomerular filtration rate 30chronic kidney disease RISK chronic kidney disease function in people with extremes of body size, 44 muscular diseases or amputations calculators can Stage 4 VERY HIGH be used to factor in body weight (see RESOURCES); RISK chronic kidney disease estimated glomerular filtration rate 15- Abnormalities persisting less than 3 months 29 indicate acute kidney injury (acute kidney injury) which increases Stage 5 the risk of subsequent chronic kidney disease. Episodes of acute kidney injury estimated glomerular filtration rate 15 should be investigated for a cause and documented or dialysis in the medical record; Newly abnormal estimated glomerular filtration rate should be repeated within a week to identify rapidly declining renal function. Screening Isolated proteinuria in a person without other risk factors for chronic kidney disease: Collect a first void urine when the patient has not undertaken heavy exercise in the Up to 60% of adults in some Kimberley previous 24 hours to recheck. communities have markers of Chronic Kidney Proteinuria with suspected urinary tract infection Disease (chronic kidney disease). Be mindful that increased or urethritis / STI: Send urine for MCS and ensure creatinine occurs late in chronic kidney disease and implies appropriate UTI / STI treatment. Repeat Urine MCS significant kidney damage. with proof of cure of the treated infection in three months or as clinically indicated. Pg.",
    "with proof of cure of the treated infection in three months or as clinically indicated. Pg. 1 of 2 Endorsed by KAHPF 12/07/2022 - KAHPF Kimberley Clinical Protocols Chronic Kidney Disease (chronic kidney disease) BOX 1: RISK FACTORS FOR UROLOGICAL MALIGNANCY Principles of Management Age 35 years; Smoking history (risk correlates with exposure); Assessment of chronic kidney disease: History of macroscopic haematuria; All patients with confirmed chronic kidney disease require: History of other less common risk factors: chronic cystitis or irritative voiding symptoms; pelvic blood pressure, body mass index, check for peripheral oedema; irradiation, exposure to cyclophosphamide; Renal tract ultrasound; aristolochic acid; occupational exposures; chronic FBP, CRP, iron studies, uric acid, LFT, calcium / indwelling foreign body; previous analgesic abuse. magnesium / phosphate, lipids parathyroid hormone (if calcium or phosphate are abnormal); Management of chronic kidney disease: Hepatitis C and HIV serology if not done within the PREVENT PROGRESSION TO end-stage kidney disease AND REDUCE last 12 months, with appropriate counselling; CARDIOVASCULAR RISK Hepatitis B serology, if not known to be immune; People with moderate or severe chronic kidney disease (albumin-creatinine ratio hemoglobin hemoglobin A1c: 30mg/mmol or estimated glomerular filtration rate 45) are at the highest If diabetic and not done within the last 3 months; cardiovascular risk category, regardless of their o score on absolute cardiovascular risk tools. Otherwise, if not done within the last 12 months. o Address all identified cardiovascular risk factors. If albumin-creatinine ratio 30 and not previously done: Serum protein Smoking cessation helps prevent progression to electrophoresis, urine protein electrophoresis, chronic kidney disease. See SMOKING CESSATION and complements, ANA, ENA; HYPERLIPIDAEMIA protocols; If haematuria and not previously done: ANCA, anti- Optimise control for patients with diabetes (see GBM DIABETES protocol). Individualise hemoglobin hemoglobin A1c target If haematuria and additional risk factors for between 6. 5 8% based on hypoglycaemia risk; malignancy (see Box 1): as above plus cystoscopy A healthy body weight and maintaining a healthy and/or urology referral, cytology x 3 (consider that diet helps reduce progression to end-stage kidney disease. See transport delays may affect results). HEALTHY LIFESTYLE protocol. Haematuria is: Microscopic: hemoglobin on dipstick OR red blood cell on urine MCS, ENSURE ROUTINE IMMUNISATIONS UP TO DATE In chronic kidney disease stage 4 5, also ensure HBV immune: Follow on two separate occasions at least a week apart, not the Australian Immunisation Handbook. associated with infection or menstruation, OR: Macroscopic: Red, brown or dark discoloration of PREVENT ACUTE KIDNEY INJURY (acute kidney injury): urine observed by patient or staff / - clots. Confirm Consider nephrotoxicity when prescribing and where possible by dipstick or urine MCS. Requires advise re: OTC medications such as NSAIDS (see urgent follow-up. Table 4). In acutely unwell patients with chronic kidney disease: Microscopic haematuria may indicate Check weight, blood pressure, fluid status and UEC regularly; glomerulonephritis. Specify if patient has haematuria on Consider temporarily ceasing sulphonylureas / ACErenal referral and investigate appropriately (see baseline I / diuretics / metformin / angiotensin receptor blocker / NSAIDS / SGLT-2-I assessment). Confirm haematuria when the patient is not menstruating if possible. (SADMANS mnemonic), especially with hypotension / hypovolaemia (if unsure contact physician / Macroscopic haematuria requires urgent urological nephrologist for advice); follow-up to exclude malignancy, regardless of Recheck UEC once acute illness has resolved to whether a urine MCS has bacterial growth, as determine new baseline and ensure ceased malignancy predisposes to UTI. medications are restarted if appropriate. Pg.",
    "medications are restarted if appropriate. Pg. 2 of 2 Endorsed by KAHPF 12/07/2022 - KAHPF Kimberley Clinical Protocols Chronic Kidney Disease (chronic kidney disease) Therapeutic Protocols symptomatic or persistent hypocalcaemia despite cholecalciferol OR elevated parathyroid hormone ≥ 5 x ULN: USE AN angiotensin-converting enzyme inhibitor/angiotensin receptor blocker UNLESS CONTRAINDICATED Consider calcitriol in discussion with renal GP or nephrologist. Calcium levels and parathyroid hormone should be closely For all patients with proteinuria (albumin-creatinine ratio 30mg/ monitored when introducing or increasing calcitriol mmol, or 3 magnesium/mmol and diabetes mellitus, IHD or hypertension): doses. Hypercalcaemia may require cessation of Prescribe an angiotensin-converting enzyme inhibitor OR angiotensin receptor blocker for all patients without cholecalciferol, caltrate or calcitriol. contraindications, to reduce overall mortality and progression to end-stage kidney disease. Titrate to maximum dose Acidosis (serum bicarbonate 15 millimoles per liter): tolerated without symptomatic hypotension. Monitor If persists AFTER correction of hypocalcaemia, can be blood pressure, UEC fortnightly during up-titration. Creatinine treated with sodium bicarbonate tablets (SodiBic 840mg) 1 BD, up to 2 tablets TDS to a target of 22 millimoles per liter. increase 30% within a month of commencement / Monitor for exacerbation of hypertension and heart failure dose increase is acceptable. Seek advice if: (increased salt load). Potassium ≥6. 0 millimoles per liter consider drug o interactions eg. spironolactone; dietician referral; Anaemia and iron deficiency: o Creatinine rise 30% consider bilateral renal Anaemia occurs in late chronic kidney disease due to both iron deficiency artery stenosis. and reduced red blood cell production, and can be exacerbated by Do not combine ACE and angiotensin receptor blocker due to risk of acute kidney injury. fluid overload. Exclude other causes of anaemia in early chronic kidney disease, with absolute iron deficiency or in refractory Once angiotensin-converting enzyme inhibitor or angiotensin receptor blocker maximised, use other agents as anaemia. General guidelines: needed to control blood pressure to goal of 130/80 unless other TF saturation 20% and hemoglobin 110: Treat for iron target specified by nephrologist / physician (see deficiency, check B12 / folate. Oral iron is poorly HYPERTENSION protocol). absorbed in chronic kidney disease. Refer for iron infusion if no For other patients with chronic kidney disease, use angiotensin-converting enzyme inhibitor or angiotensin receptor blocker improvement after one month or first line in chronic kidney disease 5; as the preferred first option for managing hypertension. TF saturation 20% and hemoglobin 100: May require erythropoietin stimulating agent (erythropoiesis-stimulating agent) (eg. TABLE 2: angiotensin-converting enzyme inhibitor AND angiotensin receptor blocker ON THE KSDL KSDL Supplementary list Mircera). Discuss with renal GP / nephrologist. ACERamipril: (2. 5mg, Enalapril: (5mg, 10mg, Inhibitors 5mg, 10mg tab) 20mg tab) Symptoms of end-stage kidney disease: Quinapril: (5mg, 10mg, Should be assessed for regularly: 20mg tab) Ask about nausea, vomiting, anorexia, lethargy, Quinapril / hematocrit: (20mg / 12. 5mg tab) SOB, pruritis, leg swelling, restless leg symptoms angiotensin receptor blocker Irbesartan: (75mg, Irbesartan / hematocrit: and chest pain. 150mg, 300mg tab) (300mg/12. 5mg tab) Monitor for infections. Patients with chronic kidney disease are TREAT COMPLICATIONS OF LATE chronic kidney disease (STAGES 3B-5): immunosuppressed and vulnerable to infections. Hyperparthyroidism of renal disease: Severe infections may occur without prominent Hyperphosphataemia requires dietary advice / - fever and dose adjustment of antibiotics may be dietician referral / - phosphate binders (eg. caltrate, needed. Contact renal GP, physician or sevelamer). Binders must be taken with food to work nephrologist for advice as needed. and should be timed to correspond to larger meals. Initiate advanced care planning processes and refer to the pre-dialysis co-ordinator for support Mild hypocalcaemia (calcium ≥ 1.",
    "Initiate advanced care planning processes and refer to the pre-dialysis co-ordinator for support Mild hypocalcaemia (calcium ≥ 1. 9 millimoles per liter) without in counselling and renal pathway planning. symptoms: Check vitamin D level and supplement Consider a palliative care referral if appropriate. with cholecalciferol as needed to achieve levels 50nmol/L. Moderate hypocalcaemia (calcium ≤ 1. 9 millimoles per liter), Pg. 3 of 2 Endorsed by KAHPF 12/07/2022 - KAHPF Kimberley Clinical Protocols Chronic Kidney Disease (chronic kidney disease) TABLE 3: COMMONLY PRESCRIBED DRUGS Refer Discuss WHICH REQUIRE CAUTION IN chronic kidney disease TO KIMBERLEY RENAL SERVICES: Drug Risks in chronic kidney disease / Action required Via MMEx to KRS Kimberley Diabetes management Via email to krsadminkamsc. org. au OR Insulin Accumulation, increased risk of Via fax to 08 9191 8600 (call 9191 8600 to confirm receipt). hypoglycaemia. Dose adjust based on BSL monitoring. chronic kidney disease patients of any stage. Please include serum Gliclazide Accumulation, increased risk of creatinine trend over time, urine albumin-creatinine ratio and renal tract hypoglycaemia. Dose adjust: estimated glomerular filtration rate 45-60: Reduce dose, estimated glomerular filtration rate 45: Cease. ultrasound results with referral unless not available. Metformin May increase risk of lactic acidosis, Referrals will be triaged and allocated to a nephrology particularly when unwell. Withhold if or renal GP clinic. Indications for nephrology review unwell. Dose adjust: estimated glomerular filtration rate 30-45: Max include: 1g/day; estimated glomerular filtration rate 30: Cease, or discuss with Persistent haematuria plus proteinuria; nephrologist / on-call physician. Proteinuria 1g/day (albumin-creatinine ratio 70, protein-creatinine ratio 100); Sitagliptin Accumulation, drug toxicity. Dose adjust: Patients with very high risk chronic kidney disease; estimated glomerular filtration rate 30-50: 50mg daily, estimated glomerular filtration rate 30: 25mg daily OR use Linagliptin. chronic kidney disease and difficult to manage hypertension on three agents; Empagliflozin Mechanism of action dependent on estimated glomerular filtration rate. If Persisting anaemia despite iron therapy. estimated glomerular filtration rate persistently 45: Cease, or discuss with nephrologist / physician. URGENT DISCUSSION (ON CALL RENAL GP Other OR NEPHROLOGIST): Atenolol Accumulation may cause bradycardia, Abnormal estimated glomerular filtration rate / albumin-creatinine ratio and suspected connective especially in acute kidney injury (monitor closely). tissue disease (eg. facial rash, polyarthritis, lethargy, Diuretics Volume depletion, contributing to acute kidney injury. Electrolyte disturbance. Withhold if unwell abnormal investigations); or dehydrated. Monitor UEC regularly. Possible nephrotic syndrome (heavy proteinuria Colchicine Accumulation, drug toxicity. Adjust dose (albumin-creatinine ratio220), oedema, hypoalbuminaemia, Digoxin according to estimated glomerular filtration rate (see eTG) / - monitor Gentamicin levels. hyperlipidaemia); Vancomycin Rapidly declining renal function (estimated glomerular filtration rate decline by angiotensin-converting enzyme inhibitor, angiotensin receptor blocker May increase risk of acute kidney injury during acute 15mL/min within 12 months). illness. Hyperkalaemia. Monitor potassium. Withhold if unwell. Cease if estimated glomerular filtration rate 15 and TO OBSTETRICIAN if chronic kidney disease and planning not required for hypertension. pregnancy or early pregnancy. NSAIDS Increase risk of acute kidney injury. Avoid. Radiological Avoid unnecessary contrast in chronic kidney disease stages TO ALLIED HEALTH as part of a Team Care contrast media 4/5 or stage 3b with additional acute kidney injury factors. Arrangement, and particularly chronic kidney disease with: Risk reduction by IV pre-hydration and withholding other nephrotoxic agents may Diabetes educator: Poor diabetic control or on be needed. Provide all information on insulin; radiology form. Consider discussion with Dietician: Suspected malnutrition (unplanned weight radiologist and nephrologist. loss 10%, body mass index 18. 5, low albumin, low phosphate), Trimethoprim / Reduce tubular secretion of creatinine potassium, causing Cotrimoxazole hyperkalaemia and appearance of acute kidney injury. hyperkalaemia, hyperphosphataemia or fluid overload.",
    "hyperkalaemia, hyperphosphataemia or fluid overload. Women of childbearing age: Encourage use of reliable contraception, preTO SOCIAL / EMOTIONAL WELLBEING: pregnancy counselling and early antenatal care. Patients impacted by physiological and psychological changes of chronic kidney disease / end-stage kidney disease treatment. Stop angiotensin-converting enzyme inhibitor / ARBs as soon as pregnancy planned or suspected, and replace with pregnancy-safe antiCall your local renal health centre for support regarding hypertensive agent if required. If pregnant, discuss the care of patients with chronic kidney disease in the Kimberley region. with obstetrician / physician promptly and consider Appropriate early referral and management improves early referral to high-risk pregnancy clinic. outcomes. If breastfeeding, use enalapril as preferred ACE/angiotensin receptor blocker. Pg. 4 of 2 Endorsed by KAHPF 12/07/2022 - KAHPF Kimberley Clinical Protocols Chronic Kidney Disease FOLLOW-UP OF STABLE chronic kidney disease PATIENTS BY RISK CATEGORY chronic kidney disease STAGES chronic kidney disease RISK CATEGORY MODERATE RISK: HIGH RISK: VERY HIGH RISK (NOT YET end-stage kidney disease) end-stage kidney disease chronic kidney disease STAGE 1 AND 2 estimated glomerular filtration rate 60 Microalbuminuria estimated glomerular filtration rate 60 Macroalbuminuria chronic kidney disease STAGE 3 estimated glomerular filtration rate 45-60 Normal albumin-creatinine ratio estimated glomerular filtration rate 45 60 Microalbuminuria estimated glomerular filtration rate 45 60 Macroalbuminuria chronic kidney disease STAGE 3B estimated glomerular filtration rate 30 45 Normal albumin-creatinine ratio estimated glomerular filtration rate 30 45 Microalbuminuria chronic kidney disease STAGE 4 estimated glomerular filtration rate 15 30 chronic kidney disease STAGE 5 estimated glomerular filtration rate 15 PATHOLOGY: UEC, albumin-creatinine ratio, LFT, FBP, CRP, 12 monthly 3 6 monthly 1 3 monthly Monthly calcium, magnesium, phosphate hemoglobin hemoglobin A1c, lipids 12 monthly, more often for other conditions as needed (eg. diabetes) parathyroid hormone Every three months Iron studies As needed for the investigation and management of anaemia. Monthly if hemoglobin 100, Monthly otherwise 3 monthly CLINICAL REVIEW: blood pressure, weight, assess smoking, 12 monthly 3 6 monthly 1 3 monthly Monthly diet, exercise Symptoms of end-stage kidney disease 1 3 monthly Monthly Review by renal GP At any stage, on referral from primary provider Review by nephrologist and On referral from primary provider 3 6 monthly Each opportunity pre-dialysis coordinator Does not apply to patients who are unstable or who have rapidly changing renal function Resources Kidney Health Australia for: Chronic Kidney Disease (chronic kidney disease) Management in Primary Care: kidney disease-management-handbook; chronic kidney disease-Go! app for health professionals: kidney disease-management-handbook/chronic kidney disease-go-app; Patient information sheets also available. Caring for Australasians with Renal Impairment Guidelines, Kidney Health Australia: KRS contact list: See or call 08 9191 8600 to request a copy. On-call renal GP mobile: 0427 808 873. For an acutely unwell patient requiring transfer or outside of dialysis unit operating hours, contact nephrology service through Royal Perth Hospital. Creatinine clearance calculators: filtration rate-calculator HealthPathways Chronic Kidney Disease: Pg. 5 of 2 Endorsed by KAHPF 12/07/2022 - KAHPF"
  ],
  "metadatas": [
    {
      "source": "KAHPF+Chronic+Kidney+Disease+(CKD)+Protocol_endorsed+12.07.22.pdf",
      "chunk_id": 0,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 578,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,albuminuria,proteinuria,creatinine,urea,magnesium,dialysis",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "KAHPF+Chronic+Kidney+Disease+(CKD)+Protocol_endorsed+12.07.22.pdf",
      "chunk_id": 1,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 568,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,creatinine,calcium,phosphate,magnesium,uric acid,hemoglobin,parathyroid hormone",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "KAHPF+Chronic+Kidney+Disease+(CKD)+Protocol_endorsed+12.07.22.pdf",
      "chunk_id": 2,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 590,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,proteinuria,creatinine,sodium,potassium,calcium,phosphate,magnesium,bicarbonate",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "KAHPF+Chronic+Kidney+Disease+(CKD)+Protocol_endorsed+12.07.22.pdf",
      "chunk_id": 3,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 594,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,renal function,proteinuria,creatinine,potassium,calcium,phosphate,vitamin D",
      "year": "2025",
      "organization": "Unknown"
    },
    {
      "source": "KAHPF+Chronic+Kidney+Disease+(CKD)+Protocol_endorsed+12.07.22.pdf",
      "chunk_id": 4,
      "content_type": "reference",
      "content_type_confidence": 2,
      "word_count": 484,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,renal function,creatinine,calcium,phosphate,magnesium,hemoglobin,parathyroid hormone,iron",
      "year": "2025",
      "organization": "Unknown"
    }
  ],
  "ids": [
    "kahpf+chronic+kidney+disease+(ckd)+protocol_endorsed+12.07.22_0",
    "kahpf+chronic+kidney+disease+(ckd)+protocol_endorsed+12.07.22_1",
    "kahpf+chronic+kidney+disease+(ckd)+protocol_endorsed+12.07.22_2",
    "kahpf+chronic+kidney+disease+(ckd)+protocol_endorsed+12.07.22_3",
    "kahpf+chronic+kidney+disease+(ckd)+protocol_endorsed+12.07.22_4"
  ]
}